Investigational New Drugs

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev et al. · 2016 · 884 citations · Full text

Medicine, Oncology, Pharmacology +8

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

Stephanie Green, Geoffrey R. Weiss · 1992 · 616 citations

Medicine, Oncology, Medical Oncology +14

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen et al. · 1994 · 441 citations

Medicine, Oncology, Pharmacology +11

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Jonathan E. Rosenberg, Richard Bambury, Eliezer M. Van Allen et al. · 2013 · 411 citations · Full text

Medicine, Cancer Biology, Oncology +14